Reaction
Myasthenia Gravis Crisis reporting signals
As of the last recalculation, Myasthenia Gravis Crisis appears in 1,415 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is RAVULIZUMAB (PRR 159.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ravulizumab | 133 | 159.7 | 161.3 |
| Eculizumab | 203 | 64.0 | 64.2 |
| Human Immunoglobulin G | 42 | 30.8 | 30.9 |
| Daptomycin | 18 | 29.1 | 29.1 |
| Ceftriaxone | 37 | 17.0 | 17.0 |
| Ceftriaxone Sodium | 40 | 15.8 | 15.8 |
| Azathioprine | 82 | 14.5 | 14.5 |
| Magnesium Sulfate In Water For | 11 | 12.8 | 12.8 |
| Magnesium Sulfate Heptahydrate | 11 | 12.5 | 12.5 |
| Magnesium Sulfate | 11 | 12.5 | 12.5 |
| Amikacin | 12 | 10.4 | 10.4 |
| Pyrazinamide | 6 | 9.4 | 9.4 |
| Mycophenilic Acid | 13 | 9.3 | 9.3 |
| Belimumab | 11 | 5.1 | 5.1 |
| Pembrolizumab | 35 | 5.0 | 5.0 |
| Nivolumab | 30 | 4.6 | 4.6 |
| Remdesivir | 4 | 4.4 | 4.4 |